Physician profile
David Chen
NPI 1609868918
$1,415.63
in general payments reported to CMS, 2019-2025
12 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $242 · 2022: $236 · 2023: $177 · 2024: $14.62 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $462.50 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $235.61 | 2022 | |
| Abbvie INC. | $176.99 | 2023-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $139.31 | 2019 | |
| Allergan, INC. | $125.44 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $117.22 | 2019 | |
| Livanova USA, INC. | $63.06 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $27.33 | 2019 | |
| Ucb, INC. | $25.02 | 2019 | |
| Lundbeck LLC | $16.61 | 2023 | Rexulti |
| Corium, LLC | $15.15 | 2023 | Adlarity |
| Amneal Pharmaceuticals LLC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.